
|Articles|April 1, 2004
New biological treatments show promise for psoriasis
Washington - Biological treatments for psoriasis have largely unraveled the once-secret mechanisms behind this disease. "The biologics including Amevive [alefacept], Raptiva [efalizumab], Embrel [etanercept], and Remicade [infliximab] are scientifically revolutionary and exciting," said John Y. M. Koo, M.D., who spoke about these treatments at the American Academy of Dermatology meeting. Board-certified in dermatology and psychiatry, he is professor and vice chairman of the University of California at San Francisco's department of dermatology.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Clinicians Weigh Topical Sequencing and Escalation in Complex Atopic Dermatitis Cases
2
Phase 3 STOP-HS Trials Highlight Promise of Oral JAK1 Inhibition for Moderate to Severe Disease
3
Sonelokimab Meets Primary End Point in Phase 3 Psoriatic Arthritis Trial
4
Common Mistakes in Managing Hair Loss and Pigmentary Disorders
5











